Back to School: How biopharma can reboot drug development. Access exclusive analysis here

The other way around EGF

In the late 1980s, when Cuban scientists began developing active and passive immunotherapies against epidermal growth factor (EGF) and its receptor, virtually all other efforts were targeting EGFr rather than the growth factor itself. Of the five major products on the market or in late- stage clinical trials, all are focused on EGFr, by inhibiting either EGFr signaling or the tyrosine kinase activity of EGFr. The Cubans are targeting EGF itself via a therapeutic vaccine, SAI-EGF (specific active immunotherapy EGF), which triggers the immune system to

Read the full 865 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE